306 related articles for article (PubMed ID: 22771546)
1. Self-assembling CpG DNA nanoparticles for efficient antigen delivery and immunostimulation.
Rattanakiat S; Nishikawa M; Takakura Y
Eur J Pharm Sci; 2012 Sep; 47(2):352-8. PubMed ID: 22771546
[TBL] [Abstract][Full Text] [Related]
2. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
[TBL] [Abstract][Full Text] [Related]
3. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
[TBL] [Abstract][Full Text] [Related]
4. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles.
Zhang XQ; Dahle CE; Baman NK; Rich N; Weiner GJ; Salem AK
J Immunother; 2007; 30(5):469-78. PubMed ID: 17589287
[TBL] [Abstract][Full Text] [Related]
5. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
[TBL] [Abstract][Full Text] [Related]
6. Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice.
Zhu FG; Kandimalla ER; Yu D; Tang JX; Agrawal S
Int Immunopharmacol; 2004 Jul; 4(7):851-62. PubMed ID: 15182725
[TBL] [Abstract][Full Text] [Related]
7. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.
Chikh G; de Jong SD; Sekirov L; Raney SG; Kazem M; Wilson KD; Cullis PR; Dutz JP; Tam YK
Int Immunol; 2009 Jul; 21(7):757-67. PubMed ID: 19502586
[TBL] [Abstract][Full Text] [Related]
8. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
9. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination.
Bal SM; Hortensius S; Ding Z; Jiskoot W; Bouwstra JA
Vaccine; 2011 Jan; 29(5):1045-52. PubMed ID: 21129393
[TBL] [Abstract][Full Text] [Related]
10. Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in NC/Nga mice.
Inoue J; Yotsumoto S; Sakamoto T; Tsuchiya S; Aramaki Y
Pharm Res; 2005 Oct; 22(10):1627-33. PubMed ID: 16180119
[TBL] [Abstract][Full Text] [Related]
11. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice.
Bal SM; Slütter B; Verheul R; Bouwstra JA; Jiskoot W
Eur J Pharm Sci; 2012 Mar; 45(4):475-81. PubMed ID: 22009113
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides.
Inoue J; Aramaki Y
Vaccine; 2007 Jan; 25(6):1007-13. PubMed ID: 17049678
[TBL] [Abstract][Full Text] [Related]
13. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant activity of CpG-ODN formulated as a liquid crystal.
Sánchez Vallecillo MF; Ullio Gamboa GV; Palma SD; Harman MF; Chiodetti AL; Morón G; Allemandi DA; Pistoresi-Palencia MC; Maletto BA
Biomaterials; 2014 Mar; 35(8):2529-42. PubMed ID: 24382332
[TBL] [Abstract][Full Text] [Related]
15. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.
Wilson KD; Raney SG; Sekirov L; Chikh G; deJong SD; Cullis PR; Tam YK
Int Immunopharmacol; 2007 Aug; 7(8):1064-75. PubMed ID: 17570323
[TBL] [Abstract][Full Text] [Related]
16. Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in mice.
Inoue J; Yotsumoto S; Sakamoto T; Tsuchiya S; Aramaki Y
J Control Release; 2005 Nov; 108(2-3):294-305. PubMed ID: 16209897
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles.
Zhang XQ; Dahle CE; Weiner GJ; Salem AK
J Pharm Sci; 2007 Dec; 96(12):3283-92. PubMed ID: 17497736
[TBL] [Abstract][Full Text] [Related]
18. Synergistic stimulation of antigen presenting cells via TLR by combining CpG ODN and poly(γ-glutamic acid)-based nanoparticles as vaccine adjuvants.
Shima F; Uto T; Akagi T; Akashi M
Bioconjug Chem; 2013 Jun; 24(6):926-33. PubMed ID: 23631730
[TBL] [Abstract][Full Text] [Related]
19. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen.
Lee YR; Lee YH; Im SA; Yang IH; Ahn GW; Kim K; Lee CK
Arch Pharm Res; 2010 Nov; 33(11):1859-66. PubMed ID: 21116790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
